Preeclampsia Diagnostics Market Set to Reach Single-Digit Growth Rate by 2027

Preeclampsia is a serious pregnancy-related condition characterized by elevated blood pressure and excess protein in the urine, posing significant risks to both mothers and infants globally. It often leads to premature and underweight births and is a prominent hypertensive disorder during pregnancy in developed and emerging nations. Failure to diagnose preeclampsia early can result in complications such as preterm birth, organ failure, seizures, eclampsia, and potentially fatal outcomes for both mother and baby. The only cure for preeclampsia at present is delivery, which significantly increases the difficulties associated with preterm births, neonatal morbidity, and perinatal mortality. Regular prenatal care and monitoring are essential for early detection and effective management of this condition.

Preeclampsia Diagnostics Global Market Dynamics

Preeclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to organs, typically the liver and kidneys. The rising incidence of preeclampsia globally has been a significant driver for the development of new diagnostic and therapeutic solutions. Ongoing advancements in diagnostic technologies have led to improved and early detection of preeclampsia, facilitating timely intervention and management. For instance,

• In November 2022, Biora Therapeutics, Inc. disclosed the successful completion of a licensing agreement with Avero Diagnostics (formerly Northwest Pathology) for the commercial development of its Preecludia™ rule-out test for preeclampsia

Pharmaceutical companies and research institutions are actively involved in R&D efforts to develop effective and less invasive solutions for preeclampsia, which can further drive market growth. Increased awareness of preeclampsia and government initiatives, along with funding for research projects, contribute to the market's growth. Collaborations between pharmaceutical companies, academic institutions, and healthcare organizations are crucial in advancing research and developing new solutions for preeclampsia. Efforts to educate patients and healthcare professionals about the risks and early signs of preeclampsia contribute to early diagnosis and treatment, positively impacting the market.

Fill out the "Quick Inquiry Form" to request a sample copy

Preeclampsia: Risk Factors, Diagnosis, and the Quest for Predictive Biomarkers

Preeclampsia, a common condition in pregnancy is on the rise globally. The need for diagnostic tests for preeclampsia has escalated due to elevated blood pressure during pregnancy, attributed to lifestyle changes, inadequate diet, sedentary habits, alcohol consumption, and mental stress. The increasing occurrences of preeclampsia can be attributed to risk factors such as advanced maternal age, obesity, and diabetes.

For many years, physicians have commonly used blood pressure and urine protein measurements to assess the likelihood of a woman developing preeclampsia. However, these tests prove inadequate in predicting the development of severe preeclampsia, particularly as the pregnancy advances. Preeclampsia lacks a dedicated diagnostic test, and the sole curative measure involves delivering both the baby and the placenta, with the latter thought to be a contributing factor to the condition. In cases where the infant may not survive outside the womb, healthcare professionals employ a conservative approach to manage the mother's condition, utilizing antihypertensive medications, magnesium, and steroids.

Recently there has been a growing focus on predictive biomarkers for preeclampsia. A reliable predictive test simplifies early diagnosis, enables targeted surveillance, and facilitate timely delivery. A biomarker capable of identifying high-risk women in early pregnancy holds clinical significance in preventing preterm preeclampsia. For instance,

• In June 2023, Diabetomics presented the results of clinical studies on first-trimester screening and diagnostic support for preeclampsia at the 20th World Congress in Fetal Medicine in Valencia, Spain. The result stated that the addition of GlyFn as a supplementary biomarker to the FMF 'Triple' screening test for preterm preeclampsia has notably improved the screening performance, but further validation in diverse populations is necessary to confirm these findings
• In May 2023, Thermo Fisher's received FDA approval for its immunoassays designed for the evaluation of preeclampsia risk. These are the first immunoassays to receive breakthrough designation and FDA clearance, which will assess the risk of developing preeclampsia and support clinical management, marking a significant advancement in addressing this severe pregnancy complication

Key Constraints/Challenges

The complex nature of preeclampsia necessitates a multidisciplinary approach, involving specialists in maternal-fetal medicine, obstetricians, and various healthcare professionals. The integration of such services may encounter barriers, posing challenges to market growth. The lack of awareness about preeclampsia in developing countries along with inadequate awareness among healthcare providers about effective screening tools for the condition is expected to hinder market expansion in emerging countries.

North America Accounts for the Largest Share of the Global Market

The North America region is leading the global market for preeclampsia diagnostics, holding the largest market share. This dominance is attributed to the rising healthcare expenditure, widespread adoption of advanced products, and favourable initiatives by the government, acknowledging the severity of the condition. The growing prevalence of preeclampsia is resulting in escalated medical treatment costs for women affected by preeclampsia and their newborns. The Asia-Pacific region is anticipated to grow at the highest CAGR, mainly attributed to the high pregnancy rate, rising awareness about the disease and the increasing population in the region.

Competitive Landscape

The global preeclampsia diagnostics market is dominated by some of the key players which include Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG Instruments GMBH, Metabolomic Diagnostics Ltd., Bayer AG, Sera Prognostics, and Diabetomics, Inc. among others.

Organic and Inorganic Growth Strategies Adopted by Players to Establish Their Foothold in the Market

Players operating in this market are adopting both organic and inorganic growth strategies such as receiving grants for research, entering into collaborations, and acquiring related firms to garner market share. For instance,

• In February 2023, Boston University's Wendy Kuohung, MD, received a grant of $99,994 USD from the Preeclampsia Foundation for new research aimed at investigating genetic targets with the potential to develop therapeutics/diagnostic solutions for preeclampsia.
• In May 2022, Sera Prognostics Inc., recognized as The Pregnancy Company®, in collaboration with the Newborn Foundation, unveiled the initiation of the Every Mother, Every Baby Project. This initiative aims to reduce maternal and neonatal mortality and morbidity by addressing risks linked to unexpected preterm birth.

The market is expected to grow due to the rising prevalence of preeclampsia, increasing R&D initiatives for preeclampsia biomarkers, growing demand for advanced diagnostic tests, and aggressive organic and inorganic growth strategies followed by the players.

Preeclampsia Diagnostics Market Scope